Michael Thiele

Vienna, 1030, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Detection of Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Biological Samples Using Enzyme-Linked Immunosorbent Assay (ELISA).

Detection of Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Biological Samples Using Enzyme-Linked Immunosorbent Assay (ELISA).

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 13, 2026

Integrating In Silico and In Vitro Tools for Optimized Antibody Development-Design of Therapeutic Anti-oxMIF Antibodies.

Integrating In Silico and In Vitro Tools for Optimized Antibody Development-Design of Therapeutic Anti-oxMIF Antibodies.

Journal: Antibodies (Basel, Switzerland)

Published: November 12, 2024

Targeting of oxidized Macrophage Migration Inhibitory Factor (oxMIF) with antibody ON104 attenuates the severity of glomerulonephritis.

Targeting of oxidized Macrophage Migration Inhibitory Factor (oxMIF) with antibody ON104 attenuates the severity of glomerulonephritis.

Journal: PloS one

Published: May 24, 2024

Redox-dependent plasticity of oxMIF facilitates its interaction with CD74 and therapeutic antibodies.

Redox-dependent plasticity of oxMIF facilitates its interaction with CD74 and therapeutic antibodies.

Journal: Redox biology

Published: April 19, 2024

Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer.

Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer.

Journal: Molecular cancer therapeutics

Published: February 01, 2024

The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis.

The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis.

Journal: European journal of pharmacology

Published: May 08, 2023

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic.

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic.

Journal: Molecular cancer therapeutics

Published: October 18, 2022

OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases.

OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases.

Journal: Journal for immunotherapy of cancer

Published: September 12, 2022

Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics.

Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics.

Journal: Antibodies (Basel, Switzerland)

Published: July 23, 2019

Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch.

Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch.

Journal: Biochemistry

Published: February 08, 2018

Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis.

Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis.

Journal: European journal of pharmacology

Published: October 17, 2017

Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer.

Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer.

Journal: Oncotarget

Published: March 18, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026